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The chemicals in smoke may interact with 
antipsychotics, antidepressants, benzodiazepines,8 
oral contraceptives, inhaled corticosteroids and beta 
blockers via pharmacokinetic and pharmacodynamic 
(often nicotine-mediated) mechanisms.9
Pharmacokinetic interactions
Cigarette smoking induces the activity of cytochrome 
P450 (CYP) 1A2 (via chemicals in cigarette smoke 
such as polycyclic aromatic hydrocarbons)10 and also 
CYP2B6.11 These enzymes metabolise several clinically 
important drugs (such as antidepressants and 
antipsychotics) (Box) and a number of procarcinogens 
(such as those in cigarettes).10,12
The effect of smoking on hepatic enzymes is not 
related to the nicotine component of tobacco. 
Nicotine replacement therapy does not influence 
CYP1A2 activity.13
Genetic polymorphisms of the CYP1A2 gene 
contribute to extensive inter-individual variability in 
drug metabolism14,15 and are associated with altered 
inducibility of gene expression in smokers.7,16 There 
are also marked ethnic differences in the distribution 
of CYP1A2 mutations,10,17 meaning that different ethnic 
groups respond differently when the patient stops 
smoking. 
CYP1A2 activity is significantly higher in heavy 
smokers (more than 20 cigarettes/day) than in non-
smokers.18 This is likely to be clinically relevant for 
some drugs which have a narrow therapeutic index 
and are metabolised by CYP1A2, such as clozapine. 
The induction varies depending on the bioavailability 
of the components of cigarette smoke and the extent 
of inhalation.8 It is not known how the number of 
cigarettes smoked daily or inter-individual variation 
affects CYP1A2 induction,9 but heavier smokers appear 
to have a greater increase in the clearance of drugs.19
This enzyme induction is rapidly reversed when 
patients abruptly stop smoking, with a new steady 
state of CYP1A2 activity reached after approximately 
one week.20 This reduction in enzyme activity reduces 
clearance and increases the risk of adverse drug 
reactions for patients taking drugs metabolised by 
CYP1A2.20,21 These patients should be regularly asked 
about their smoking and the extent of their cigarette 
consumption.16
Clozapine and olanzapine
Cigarette smoking induces the metabolism of 
Introduction
Despite anti-smoking campaigns, there are about  
1.3 billion cigarette smokers worldwide and this 
number is still increasing.1 Both smoking prevalence 
and daily tobacco consumption are very high in 
patients with psychiatric disorders.2 Over two-thirds 
of Australians with psychosis smoke cigarettes, 
compared with one quarter of the general population.3
Smoking restriction or cessation is now commonly 
imposed on patients by ‘no smoking’ policies in 
Australian hospitals. Stopping smoking is particularly 
important in patients with mental health problems as 
they often have an adverse cardiovascular risk profile 
(from factors including obesity, dyslipidaemia, insulin 
resistance and hypertension). This is associated with 
high rates of premature mortality from cardiovascular 
disease.4
Even with nicotine replacement therapy as a cessation 
aid, patients with psychiatric illness appear to have 
more difficulty maintaining long-term abstinence 
than other smokers.5 Most resume smoking within 
five weeks of hospital discharge.6 These patients 
should be regularly asked about their smoking 
status, as an additional risk of resuming or abruptly 
ceasing cigarette smoking has the potential for drug 
interactions.7
SUMMARY
When patients enter hospital they may have 
to stop smoking abruptly if the hospital 
has a ‘no smoking’ policy. Abrupt smoking 
cessation can affect the metabolism of drugs.
Cigarette smoking induces the activity of 
human cytochromes P450 (CYP) 1A2 and 
2B6. These enzymes metabolise several 
clinically important drugs, including 
clozapine, olanzapine and methadone. 
Decreased CYP1A2 activity after smoking 
cessation increases the risk of adverse 
drug reactions, with reports of increased 
toxicity from clozapine and olanzapine. 
Predicting the required dose reduction of 
drugs metabolised by CYP1A2 after smoking 
cessation is challenging. Therapeutic drug 
monitoring should be used when possible.  
Nicotine replacement therapy does not 
influence CYP1A2 activity.
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the warfarin dose requirement by 12%, resulting in 
an extra 2.26 mg per week compared with non-
smoking.30 Consequently, INR should be closely 
monitored when there is a change in patients’ 
smoking status.
Clopidogrel and prasugrel
CYP isoenzymes (including CYP2C19, 3A4/5, 1A2, 
2B6 and 2C9) convert clopidogrel and prasugrel 
into their active metabolites, which bind irreversibly 
to the receptors on platelets. As smoking is 
known to enhance CYP1A2 activity, theoretically 
it could increase the antiplatelet efficacy of these 
thienopyridine drugs.31
An enhanced response to clopidogrel has been 
seen in smokers who are CYP1A2 (163CA) A-allele 
carriers.32 Two retrospective analyses of large 
randomised clinical trials of clopidogrel showed 
that clopidogrel might be more effective in active 
smokers.33,34 However, a systematic review concluded 
that smoking is not associated with reduced platelet 
reactivity in patients on clopidogrel.31 Genetic 
polymorphisms seem not to impact on the activity of 
prasugrel.31
Caffeine
Caffeine is highly dependent on CYP1A2 for its 
metabolism. Smokers require up to four times as 
much caffeine as non-smokers to achieve the same 
plasma caffeine concentration. Caffeine can increase 
the concentration of clozapine and olanzapine.35
Pharmacodynamic drug interactions
Pharmacodynamic drug interactions with tobacco 
smoke are largely due to nicotine.9
Methadone
The vast majority of patients using methadone 
maintenance therapy also smoke tobacco.36 
Methadone doses have been found to be higher 
in heavy smokers37 and methadone has been 
shown to increase both smoking rates and smoking 
satisfaction.38 Patients report less methadone-induced 
clozapine and olanzapine,22 resulting in lower 
plasma concentrations.7,16,21 The daily consumption 
of 7–12 cigarettes is probably sufficient to cause the 
maximum induction of clozapine and olanzapine 
metabolism.22 A 50% difference in the mean daily 
dose of clozapine needed by smokers and non-
smokers to reach a given blood concentration has 
been reported.23
Irrespective of smoking status, the mean oral 
bioavailability of clozapine is 27–47% and clozapine 
plasma concentrations have more than a 45-fold 
variability amongst individuals during chronic 
treatment.24 There are also large inter-patient 
differences in olanzapine exposure, with gender and 
genetic factors contributing.25
Non-smokers are at higher risk of adverse effects if 
treated with standard doses, suggesting that there 
is an interaction between smoking, olanzapine and 
clozapine.20,22 In one case report, a patient receiving 
olanzapine experienced extrapyramidal symptoms 
(including akathisia, akinesia and bradyphrenia) within 
days of significantly reducing tobacco consumption.21 
Case reports on smoking discontinuation by patients 
taking clozapine outline effects including confusion,21 
tonic–clonic seizures, stupor, coma26 or aspiration 
pneumonia.27
Clearance of clozapine has been shown to decrease 
when smoking is ceased, with a mean increase of 72% 
in plasma clozapine concentrations.27 It is suggested 
that daily dose reductions (of approximately 10% 
until the fourth day after smoking cessation) should 
be made whenever patients cease smoking during 
treatment with clozapine.20 Patients who resume 
smoking after leaving hospital may need their drugs 
and doses reviewed to account for this change.28 
Therapeutic drug monitoring of clozapine is useful.
Antidepressants
As fluvoxamine is metabolised by CYP1A2, smokers 
might require higher doses than those recommended 
from clinical trial data.8 Smoking is not anticipated to 
alter the pharmacokinetics of other selective serotonin 
reuptake inhibitors as they are not substrates of 
CYP450 isoenzymes induced by smoking.8
Smokers might require higher than normal doses of 
the tricyclic antidepressant imipramine. They do not 
appear to require dose adjustments of amitriptyline, 
nortriptyline or clomipramine.8
Warfarin
Warfarin’s less active R isomer is eliminated to a 
minor extent by CYP1A2.29 Smoking may therefore 
potentially interact with warfarin by increasing its 
clearance and reducing its effect. A recent meta-
analysis showed that smoking appeared to increase 
Box    Substrates of some cytochrome P450 enzymes induced 
by smoking
CYP1A2 
amitriptyline, caffeine, clozapine, duloxetine, fluvoxamine, haloperidol, imipramine, 
olanzapine, ondansetron, paracetamol, propranolol, theophylline, warfarin (R-isomer)
CYP2B6
bupropion, clopidogrel, cyclophosphamide, efavirenz, ifosfamide, methadone, 
nevirapine
More comprehensive lists are available8,17
Adapted from Australian Medicines Handbook 2013
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Drugs for nicotine dependence
Drugs used to aid smoking cessation are not without 
their hazards, particularly in patients with psychiatric 
disorders.
Bupropion, a selective catecholamine reuptake 
inhibitor, is associated with a dose-related risk of 
seizures. Predisposing risk factors include concomitant 
administration of antipsychotics, antidepressants, 
excessive alcohol or those sedatives which lower 
the seizure threshold. Psychiatric symptoms, in 
particular psychosis or mania, have been observed, 
mainly in patients with a history of psychiatric illness, 
particularly bipolar disorder. 
Bupropion is metabolised by CYP2B6 and inhibits 
the CYP2D6 pathway. Drugs predominantly 
metabolised by 2D6 (including metoprolol, many 
antidepressants and antipsychotics) should be started 
at the lower end of the dose range if bupropion is 
used. Co-administration of drugs known to induce 
metabolism (for example, carbamazepine and 
phenytoin) or inhibit metabolism (for example, 
valproate) may affect the activity of bupropion. 
Nortriptyline, a tricyclic antidepressant shown to aid 
smoking cessation, also interacts with other drugs 
metabolised by CYP2D6. 
Varenicline, a partial agonist at neuronal nicotinic 
acetylcholine receptors, has no known clinically 
significant drug interactions. However, using nicotine 
replacement therapy while taking varenicline can 
exacerbate adverse effects such as nausea and 
headache. As with bupropion, serious neuropsychiatric 
symptoms have been reported (although a causal 
association has not been established). 
Conclusion
Cigarette smoking can affect drug metabolism via 
pharmacokinetic and pharmacodynamic mechanisms, 
and a change in smoking status can render patients at 
risk of serious adverse reactions.
Patients should be regularly monitored with regard 
to their smoking status and extent of cigarette 
consumption and doses of relevant medications 
adjusted accordingly. 
No relevant potential conflict of interest declared
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sedation when they smoke around the time of their 
methadone dose.39
Although methadone is a CYP2B6 substrate (Box), 
nicotine affects the endogenous opioid system. 
Cigarette smoking enhances the effect of methadone 
on opioid withdrawal symptoms.40
Methadone attenuates nicotine withdrawal. Reducing 
methadone doses when the patient is trying to stop 
smoking could be detrimental.40
Benzodiazepines
Nicotine activates the central nervous system9 and 
this may explain the attenuated sedation observed 
in smokers compared to non-smokers taking 
benzodiazepines.41 Prescribers should be aware that 
when patients taking benzodiazepines stop smoking, 
there is a risk of central nervous system depression. 
Oral contraception
Smoking increases the adverse effects of the 
combined oral contraceptive pill (specifically 
thromboembolism, ischaemic stroke and myocardial 
infarction). The combined oral contraceptive pill is 
contraindicated in women aged 35 years or older 
who smoke 15 or more cigarettes a day.9 For smokers 
who use combined low-dose oral contraceptives, the 
attributable risk of death from cardiovascular disease 
is 19.4 per 100 000 women aged 35–44 years  
(vs 3.03 per 100 000 for non-smoking women of the 
same age).42 This risk is also presumed to be associated 
with other contraceptives containing oestrogen.9
Limited data suggest no convincing association 
between cardiovascular disease and progestogen-
only pill use.43 If smoking cessation is unsuccessful, 
non-hormonal or progestogen-only contraceptives 
are preferred from a cardiovascular perspective.9
Other drugs
The efficacy of inhaled corticosteroids may be 
reduced in asthmatic patients who smoke,9 so these 
patients might require higher doses of inhaled 
corticosteroids to attain asthma control.44
Proposed mechanisms of corticosteroid insensitivity 
include suppression of histone deacetylase 
expression and activity by cigarette smoking, causing 
inflammatory gene expression and a reduction in 
glucocorticoid function.45 Clearance of corticosteroids 
from the lungs may be altered by increased mucus 
secretion or airway permeability.46
Smokers may require higher doses of beta blockers. 
Although propranolol is a CYP1A2 substrate (Box), 
nicotine-mediated central nervous system activation 
may diminish the effect of beta blockers on blood 
pressure and heart rate.9
SELF-TEST 
QUESTIONS
True or false? 
9. As smoking induces 
cytochrome P450 1A2,  
smokers need lower 
doses of drugs 
metabolised by this 
enzyme.
10. The pharmacokinetic 
effects caused by 
stopping smoking can 
be avoided by giving 
the patient a nicotine 
patch.
Answers on page 107
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